1) Diagnostic biomarker identification and analysis for vascular anomalies
2) Human patient-derived cell xenograft models of vascular anomalies
3) Mouse models of vascular anomalies
4) Therapeutic targeting of vascular anomalies
1. NIH R01 HL156866
PI: Le Cras
01/01/2022-5/31/2030
“Pathogenesis and Treatment of Kaposiform Lymphangiomatosis“
Kaposiform Lymphangiomatosis (KLA) is a rare but frequently fatal lymphatic disorder that primarily affects children and young adults. We have developed novel human cell-based systems and genetic mouse models harboring the most common disease-causing mutation identified in patients with KLA. In this project, we will leverage these complementary preclinical models to define the mechanisms driving this chronic lymphatic disease and to evaluate targeted therapeutic strategies for patients with KLA.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 2026 Cincinnati Children's Hospital Medical Center. All rights reserved.
